Atay Oguzhan, the Chairman and CEO of BillionToOne, Inc., has reported several stock transactions that highlight his ongoing engagement with the company's equity. The recent transactions, filed on October 30, 2026, are significant as they reflect strategic decisions regarding stock management within the medical laboratories sector.

Background

BillionToOne, Inc. operates in the medical laboratories sector, specifically classified under the Standard Industrial Classification (SIC) code 8071. The company is incorporated in Delaware and has its business address at 1035 O'Brien Drive, Menlo Park, California. Atay Oguzhan is actively involved in the company's management as both a director and an officer.

What the Filing Says

The filing reveals that on October 28, 2026, Oguzhan acquired 8,333 shares of Class A Common Stock at a price of $2.80 per share. Additionally, he sold 8,333 shares at a price of $118 each, reducing his direct ownership to zero shares while retaining indirect ownership of 146,501 shares held by his spouse. The transactions were executed under a Rule 10b5-1 trading plan, which allows for pre-scheduled stock trades.

Impact

This update may affect shareholders and potential investors in BillionToOne, as it indicates Oguzhan's strategic approach to managing his stock holdings. The structured nature of these transactions suggests a deliberate strategy, which could influence market perceptions and investor confidence.

What's Next

The filing does not say what happens next.